Abstract
Malaria in pregnancy is a major public health issue, contributing to significantly increasing mother and children mortality and morbidity. Intermittent preventive treatment of malaria using Sulfadoxine-Pyrimethamine (IPTp-SP) is one of the key interventions recommended by WHO and in Cameroon to reduce the morbidity of Malaria in Pregnancy. The present study aims to assess the distribution and determinants of poor uptake of IPTp-SP (< 3 doses) among pregnant women in Cameroon.
We conducted a secondary analysis of data extracted from the Cameroun Demographic Health Survey conducted in 2018. Data were collected using a questionnaire administered in face to face to mothers with at least one child under 5, selected using a 2-stage stratified sampling process. Frequencies of mothers exposed to less than 3 doses of IPTp-SP were estimated with a 95% CI. A case-control design was used to assess the association between key suspected determinants and being exposed to less than 3 doses of IPTp-SP. This was measured by estimating crude and adjusted Odd-Ratios (ORs).
A total of 13527 childbearing age women were interviewed, of which 5528 (40.9%) met our selection criteria. Among those, 845 (15.3%) had not attended any Antenatal care (ANC) visit, 1109 (20%) had attended 1 to 3 visits, 3379 (61.1%) had attended 4 to 7 visits and only 195 (3.5%) had attended at least 8 visits. In all, 3398 (61.5%, CI: 60.2-62.8) had received less than 3 doses of IPTp-SP. Maternal age below 26 years (aOR=1.17, CI: 1.01-1.35), residence in an area of lower malaria endemicity (aOR=1.26, CI: 1.00-1.58), residence in the Sahelian regions (aOR=5.81, CI: 2.46-13.69), and having attended less than 4 ANC visits (aOR=1.30, CI: 1.08-1.57) were predictors of poor uptake of IPTp-SP. Conversely, residence in major cities (aOR=0.65, CI: 0.50-0.84), having attended a first ANC visit at 3 months or less of pregnancy (aOR=0.66, CI: 0.57-0.78) and having been followed on ANC by a medical doctor (aOR=0.22, CI: 0.13-0.35), were preventing factors for poor uptake of IPTp3+. Highest level of education (aOR= 1.10, CI: 0.90-1.32) was not found associated with the uptake of IPTp-SP.
Therefore, only a third of pregnant women in Cameroon take an optimal dose of IPTp-SP. This proportion vary widely with the place of residence, being significantly low in the Sahelian regions. Interventions to address identified determinants of low coverage of IPTp-SP like maternal age below 26 years, ANC characteristics or being resident of area with lower malaria endemicity ought to be tested.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Cameroon DHS protocol, including measuring procedures and biological tests, was reviewed and approved by the Cameroonian ministry of health National ethical committee for research and human health (CNERSH) and Inner-City Fund (ICF) Institutional Review Board. Informed consent for the survey was obtained from each respondent before each interview. Permission to access the Cameroonian DHS 2018 survey dataset for the present study was obtained from the Demographic and Health Surveys (DHS) Program.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
https://doi.org/10.6084/m9.figshare.21308949
https://figshare.com/articles/dataset/Finaldatabase_DHSIPTpSPAnalysis_sav/21308949